Ratings by Stephens (Mason Carrico)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/13/2026 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2025 | Natera | NTRA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2025 | Pacific Biosciences of California | PACB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/22/2025 | Hologic | HOLX | Downgrade | Equal Weight (Overweight) |
73.98 (76.01) |
2.74% | Details | |
| 9/2/2025 | Neogenomics | NEO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2025 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/9/2025 | Procept BioRobotics Corp | PRCT | New Coverage | Overweight (N/A) |
57.91 (20.85) |
-64% | Details | |
| 5/16/2025 | Cytek Biosciences Inc | CTKB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2025 | Hologic | HOLX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/25/2025 | Akoya Biosciences Inc | AKYA | Downgrade | Equal Weight (Overweight) |
1.67 (1.29) |
-22.75% | Details | |
| 1/29/2025 | Paragon 28, Inc | FNA | Downgrade | Equal Weight (Overweight) |
12.00 (13.09) |
9.08% | Details | |
| 12/11/2024 | Hologic | HOLX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/12/2024 | Illumina | ILMN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/11/2024 | Myriad Genetics | MYGN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/13/2024 | Pacific Biosciences of California | PACB | Maintain | Overweight (N/A) |
|
Details | ||
| 6/27/2024 | Hologic | HOLX | New Coverage | Overweight (N/A) |
71.65 (73.98) |
3.25% | Details | |
| 5/13/2024 | CareDx, Inc | CDNA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/17/2024 | CareDx, Inc | CDNA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2024 | DermTech Inc. | DMTK | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 12/14/2023 | Cytek Biosciences Inc | CTKB | New Coverage | Overweight (N/A) |
7.55 (4.28) |
-43.31% | Details | |
| 12/14/2023 | Pacific Biosciences of California | PACB | New Coverage | Overweight (N/A) |
8.31 (1.44) |
-82.67% | Details | |
| 12/14/2023 | Illumina | ILMN | New Coverage | Overweight (N/A) |
117.64 (175.09) |
48.84% | Details | |
| 11/13/2023 | Akoya Biosciences Inc | AKYA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2023 | CareDx, Inc | CDNA | Upgrade | Overweight (Equal Weight) |
6.33 (27.13) |
328.59% | Details | |
| 8/21/2023 | Neogenomics | NEO | Upgrade | Overweight (Equal Weight) |
13.55 (12.90) |
-4.8% | Details | |
| 5/8/2023 | DermTech Inc. | DMTK | Downgrade | Equal Weight (Overweight) |
2.31 (0.09) |
-96.1% | Details | |
| 3/31/2023 | 10X Genomics | TXG | New Coverage | Overweight (N/A) |
50.74 (34.60) |
-31.81% | Details | |
| 3/7/2023 | CareDx, Inc | CDNA | Downgrade | Equal Weight (Overweight) |
10.65 (27.13) |
154.74% | Details | |
| 3/6/2023 | Myriad Genetics | MYGN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/28/2023 | fuboTV | FUBO | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/8/2022 | DermTech Inc. | DMTK | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2022 | Guardant Health | GH | Maintain | Overweight (N/A) |
|
Details | ||
| 10/6/2022 | Guardant Health | GH | New Coverage | Overweight (N/A) |
59.62 (136.96) |
129.72% | Details | |
| 10/6/2022 | Myriad Genetics | MYGN | New Coverage | Equal Weight (N/A) |
20.61 (5.22) |
-74.67% | Details | |
| 10/6/2022 | Akoya Biosciences Inc | AKYA | New Coverage | Overweight (N/A) |
12.69 (1.29) |
-89.83% | Details | |
| 8/12/2022 | DermTech Inc. | DMTK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/24/2022 | OncoCyte Corp | OCX | Downgrade | Equal Weight (Overweight) |
1.08 (3.20) |
196.3% | Details | |
| 4/25/2022 | fuboTV | FUBO | New Coverage | Equal Weight (N/A) |
4.55 (8.75) |
92.31% | Details | |
| 4/25/2022 | CareDx, Inc | CDNA | New Coverage | Overweight (N/A) |
30.57 (27.13) |
-11.25% | Details | |
| 4/25/2022 | Natera | NTRA | New Coverage | Overweight (N/A) |
36.29 (259.97) |
616.37% | Details | |
| 3/29/2022 | Neogenomics | NEO | Downgrade | Equal Weight (Overweight) |
17.79 (12.90) |
-27.49% | Details | |
| 3/2/2022 | Veracyte, Inc | VCYT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2022 | Neogenomics | NEO | New Coverage | Overweight (N/A) |
24.94 (12.90) |
-48.28% | Details | |
| 1/7/2022 | OncoCyte Corp | OCX | New Coverage | Overweight (N/A) |
2.06 (3.20) |
55.34% | Details |

